Nuwellis, a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock, pre-funded warrants, and Series C and D warrants, with proceeds aimed at supporting the company's growth and product development. The warrants have specific exercise terms tied to stockholder approval and potential reverse stock splits. This funding will help Nuwellis advance its technologies for patient care in acute and chronic settings.
Nuwellis, Inc., a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock and warrants, priced around $0.30 per share and warrant. Proceeds will s...
Nuwellis, Inc. announced a public offering of 20 million shares of common stock and accompanying warrants priced at $0.30 each, aiming to raise approximately $6 million. The offering includes Series C and Series D warrants with exercise prices set at...
